![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Adjuvance Receives $1.47 Million from NIH for COVID-19 Vaccine
Adjuvance Receives $1.47 Million from NIH for COVID-19 Vaccine
![NIH-pic.jpg](https://www.fdanews.com/ext/resources/test/Drug-Images3/NIH-pic.jpg?t=1596147520&width=430)
Adjuvance Technologies has received $1.47 million from the NIH’s National Institutes for Allergy and Infectious Diseases (NIAID) to help develop a COVID-19 vaccine using the company’s adjuvant.
The funding will be used to test Adjuvance’s saponin-based adjuvant TQL1055 with NIAID’s SARS-CoV-2 antigen.
Derived from the bark of a South American tree, saponin-based adjuvants have been used in multiple vaccines for many years.
Upcoming Events
-
18Jul
-
21Oct